We are live on ! Find out more
FENC icon

Fennec Pharmaceuticals

96 hedge funds and large institutions have $120M invested in Fennec Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 26 increasing their positions, 24 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 8

14% more funds holding

Funds holding: 8496 (+12)

8% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 24

4.17% less ownership

Funds ownership: 49.67%45.5% (-4.2%)

8% less capital invested

Capital invested by funds: $130M → $120M (-$10.1M)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
96
Holders Change
+12
Holders Change %
+14.29%
% of All Funds
1.17%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
20
Increased
26
Reduced
24
Closed
8
Calls
$1K
Puts
Net Calls
+$1K
Net Calls Change
-$8K
Name Holding Trade Value Shares
Change
Change in
Stake
Franklin Resources
101
Franklin Resources
California
-$159K -16,978 Closed
AAP
102
Arax Advisory Partners
Colorado
-$1.76K -188 Closed
Fifth Third Bancorp
103
Fifth Third Bancorp
Ohio
-$1.48K -158 Closed
SS
104
SBI Securities
Japan
-$9 -1 Closed

FENC Hedge Fund Activity: Q4 2025 in Review

96 of the 8,226 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q4 2025, worth a combined $120M — down 7.8% from $130M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new FENC positions and 8 closed out — a net gain of 12 holders — while 26 added to existing stakes and 24 trimmed.

The largest buyer was AIGH Capital Management, adding an estimated $7.39M. The largest seller was Southpoint Capital Advisors, cutting an estimated $10.9M.

  • 96 institutional investors held Fennec Pharmaceuticals (FENC) as of Q4 2025, up from 84 in Q3 2025.
  • Funds reported $120M of Fennec Pharmaceuticals stock for Q4 2025, down 7.8% quarter-over-quarter.
  • 20 funds opened new Fennec Pharmaceuticals positions in Q4 2025 and 8 closed out, a net change of +12 holders.
  • The largest Fennec Pharmaceuticals buyer in Q4 2025 was AIGH Capital Management, an estimated $7.39M added.
  • The largest Fennec Pharmaceuticals seller in Q4 2025 was Southpoint Capital Advisors, an estimated $10.9M sold.

Based on aggregated 13F filings for Q4 2025.